Multiple Myeloma Clinical Trial

Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma

Summary

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease
Documented measurable disease
Adequate organ function
Life expectancy > 12 weeks, Eastern Cooperative Group Performance Status 0-1

Exclusion Criteria:

Plasma Cell Leukemia or History of Plasma Cell Leukemia
Patients with a history of severe hypersensitivity to DMSO should be excluded
Contraindication to fludarabine or cyclophosphamide
Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities
Active central nervous system disease involvement by malignancy or active CNS pathology

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

65

Study ID:

NCT04155749

Recruitment Status:

Recruiting

Sponsor:

Kite, A Gilead Company

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 4 Locations for this study

See Locations Near You

University of Chicago Medicine Comprehensive Cancer Center
Chicago Illinois, 60637, United States
Massachusetts General Hospital
Boston Massachusetts, 02114, United States More Info
Daniella Cook
Contact
714-307-8479
[email protected]
Matthew Frigault, MD
Principal Investigator
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02215, United States More Info
Emma Logan, BSN, RN, OCN
Contact
617-667-5984
[email protected]
Jacalyn Rosenblatt, MD
Principal Investigator
Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Danielle Nissen
Contact
414-805-0581
[email protected]
Binod Dhakal, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

65

Study ID:

NCT04155749

Recruitment Status:

Recruiting

Sponsor:


Kite, A Gilead Company

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.